➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts

Last Updated: September 24, 2020

DrugPatentWatch Database Preview

Patent: 10,183,994

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 10,183,994
Title:Anti-TNF.alpha. antibodies with pH-dependent antigen binding for improved target clearence
Abstract: The invention relates to anti-TNF.alpha. antibodies which are engineered to exhibit a pH-sensitive antigen binding. The invention is preferably directed to anti-TNF.alpha. antibody adalimumab (Humira.RTM.) or biologically active variants and fragments thereof, wherein the original adalimumab antibody or variant or fragment thereof is engineered by modifications of amino acid sequence within the variable regions. Specifically, the invention relates to adalimumab or biologically active variants or fragments thereof, wherein the CDR domains are modified by replacing one or more amino acid residues by histidine residues.
Inventor(s): Guenther; Ralf (Griesheim, DE), Becker; Stefan (Darmstadt, DE), Rhiel; Laura (Frankfurt am Main, DE), Hock; Bjoern (Maintal, DE), Schroeter; Christian (Darmstadt, DE)
Assignee: Merck Patent GmbH (Darmstadt, DE)
Application Number:15/322,893
Patent Claims:see list of patent claims

Details for Patent 10,183,994

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Abbvie Inc HUMIRA adalimumab SYRINGE 125057 001 2002-12-31   Start Trial Merck Patent GmbH (Darmstadt, DE) 2034-06-30 RX search
Abbvie Inc HUMIRA adalimumab VIAL 125057 002 2002-12-31   Start Trial Merck Patent GmbH (Darmstadt, DE) 2034-06-30 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Express Scripts
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.